| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 44.51 | 537 |
| Intrinsic value (DCF) | 0.49 | -93 |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.